-$0.29 Earnings Per Share Expected for CorMedix Inc (CRMD) This Quarter

Analysts expect CorMedix Inc (NASDAQ:CRMD) to post ($0.29) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for CorMedix’s earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.29). CorMedix posted earnings per share of ($0.70) during the same quarter last year, which indicates a positive year-over-year growth rate of 58.6%. The business is scheduled to announce its next earnings results on Tuesday, May 21st.

On average, analysts expect that CorMedix will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($1.20) to ($1.08). For the next financial year, analysts forecast that the company will post earnings of ($1.19) per share, with EPS estimates ranging from ($1.38) to ($1.00). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for CorMedix.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings results on Thursday, March 14th. The company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.00) by $2.10. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.24 million.

Shares of NASDAQ CRMD traded down $0.04 during mid-day trading on Thursday, hitting $7.99. The company had a trading volume of 465,445 shares, compared to its average volume of 604,325. CorMedix has a 1 year low of $0.85 and a 1 year high of $13.70.

CorMedix Company Profile

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Featured Story: Mutual Funds

Get a free copy of the Zacks research report on CorMedix (CRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.